Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Peptide domains that bind small molecules of industrial significance
US9617312B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9617312-B2 |
| Application number | US-201514968406-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 14, 2015 |
| Priority date | Jan 29, 2010 |
| Publication date | Apr 11, 2017 |
| Grant date | Apr 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, β carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or CBD that bind other ligands and can be used to immobilize the target binding domain on a support. One class of fusion proteins that is useful in industrial settings are fusions that contain concatemers of target binding domains, which increases the binding equivalents per molecule.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated peptide or polypeptide comprising a peptide domain that binds genistein comprising (SEQ ID NO: 122) L-X-L or L-X-X-X-L where L is leucine and each X is independently glycine, histidine, phenylalanine, serine, lysine, aspartate, glutamate or alanine. 2. The isolated peptide or polypeptide of claim 1 comprising the genistein binding domain (SEQ ID NO: 123) SLGLWHSQRHFDVHREHSRHQT.
Assignees
Inventors
Classifications
- C07K7/08Primary
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Tripeptides · CPC title
- C07K14/00Primary
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
- C07K7/06Primary
having 5 to 11 amino acids · CPC title
involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9617312B2 cover?
- Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, β carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or CBD that bind other ligands and can be used to immobilize the target binding…
- Who is the assignee on this patent?
- Univ Iowa State Res Found Inc, Archer-Daniels-Midland Company
- What technology area does this patent fall under?
- Primary CPC classification C07K7/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).